APSR2026-241

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-008
P27
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1203775-46904-AP14-008 APSR26_Poster Template_425783.pdf
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Kejing Yang * Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Hai Pan - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Diansheng Zhong - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Linlin Zhang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Kejing
Yang
yangkjyj@163.com
+8618988201298
31-40
China
Original Research
Development and Validation of a Risk Prediction Model for Resistance to First-Line Osimertinib in EGFR-TP53-Mutant Lung Adenocarcinoma
Maximum 25 words
Abstract Content
Osimertinib is the standard first-line treatment for EGFR-mutant lung adenocarcinoma. However, EGFR-TP53 co-mutations often compromise the efficacy of osimertinib monotherapy, resulting in shortened progression-free survival (PFS) and earlier development of resistance. Current clinical approaches lack dynamic predictive tools across the treatment course, limiting individualized management and the timely identification of candidates for combination therapy.
We retrospectively enrolled patients with advanced EGFR-mutant lung adenocarcinoma who received first-line osimertinib treatment. Clinical data, TP53 mutation characteristics, and concomitant genomic alterations were collected. A dual model was developed to predict resistance using PFS as endpoint: 1) Cox nomogram identifying early resistance risk (<6 months); 2) Weibull nomogram predicting median PFS, providing a warning of potential resistance time for co-mutations patients.
This study included 87 patients receiving first-line osimertinib monotherapy. Variables with a P-value < 0.1 from the univariate Cox analysis were used for model building. We constructed separate Cox proportional hazards models based on TP53 mutation type and mutation location to develop nomograms predicting the probability of resistance at 6, 12, and 24 months, with model performance validated internally. The model achieved time-dependent receiver operating characteristic (ROC) curve areas under the curve (AUC) of over 0.8 in training and validation sets. A Weibull regression model was used to build a nomogram for predicting the timing of osimertinib resistance. The model achieved a C-index of 0.79 (95% CI: 0.74 - 0.84), indicating that the model performed well.
The "risk-time" dual prediction model offers a visual reference for the full-course assessment and management. It supports precision treatment by guiding the selection of the optimal population and timing for combination therapy in patients with EGFR-TP53 co-mutations.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas
 
272